LOS ANGELES–(BUSINESS WIRE)–$APYX #APYX—The
Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of Apyx
Medical Corporation (“Apyx” or “the Company”) (NASDAQ: APYX)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
The investigation focuses on whether the Company issued false and/or
misleading statements and/or failed to disclose information pertinent to
investors. The clinical study of Apyx’s J-Plasma for dermal resurfacing
did not reach its primary efficacy endpoint. The study did not support
the Company’s application for regulatory clearance. In fact, Apyx was
unlikely to receive approval for the use of J-Plasma in dermal
resurfacing. Based on these facts, the Company’s public statements were
false and materially misleading throughout the class period. When the
market learned the truth about Apyx, investors suffered damages.
If you are a shareholder who suffered a loss, click
here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm,
1880 Century Park East, Suite 404, Los Angeles, CA 90067, at
424-303-1964, to discuss your rights free of charge. You can also reach
us through the firm’s website at www.schallfirm.com,
or by email at [email protected].
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.